text:
Redpoint Bio Reports Three Months and Nine Months Ended September 30, 2010 Results
Nov 09, 2010, 07:30 ET from Redpoint Bio Corporation
EWING, N.J., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Redpoint Bio Corporation (OTC Bulletin Board: RPBC), a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the three months and nine months ended September 30, 2010.
For the three months and nine months ended September 30, 2010, Redpoint recorded no revenue and $0.5 million of revenue, respectively. The revenues for the nine months ended September 30, 2010 were related to an upfront payment in connection with a Licensing and Commercialization Agreement that the Company entered into with International Flavors & Fragrances Inc. ("IFF") in June 2010. For the three and nine months ended September 30, 2009, Redpoint recorded no revenue and $1.9 million of revenue, respectively. The revenues for the nine months ended September 30, 2009 were primarily from the Company's prior collaboration with Givaudan.
Research and development expenses for the third quarter of 2010 were $0.8 million, compared to $1.2 million for the third quarter of 2009. Research and development expenses for the nine months ended September 30, 2010 were $2.5 million, compared to $4.6 million in the same period of 2009. The decrease in expenses was primarily attributable to the reductions in workforce as a result of the corporate restructurings that the Company announced in February and May of 2009.
General and administrative expenses for the third quarter of 2010 were $0.9 million, compared to $1.2 million for the third quarter of 2009. General and administrative expenses for the nine months ended September 30, 2010 were $2.9 million, compared to $4.2 million in the same period of 2009.
Redpoint reported a net loss for the third quarter of 2010 of $1.8 million, or $0.02 per common share, compared to $2.4 million, or $0.03 per common share, for the third quarter of 2009.
The net loss for the nine months ended September 30, 2010 was $4.9 million, or $0.06 per common share, compared to $7.0 million, or $0.09 per common share, for the nine months ended September 30, 2009.
Redpoint had approximately $1.6 million in cash and cash equivalents at September 30, 2010. In addition, in October 2010, RP44, the Company's all-natural sweetness enhancer, was determined to be Generally Recognized As Safe (GRAS), triggering a $0.5 million milestone payment which is due to the Company in connection with its June 2010 license agreement with IFF. Additionally, Redpoint is in the process of selling a portion of its New Jersey State net operating loss carryforwards and in November, the Company received notification that its diabetes program had been approved for a grant in the amount of approximately $0.25 million in connection with the Qualifying Therapeutic Discovery Project Program under section 48D of the Internal Revenue Code. The Company believes that its current capital resources, and the amounts expected to be received from the aforementioned milestone payment and government programs, are sufficient to meet its operating and capital requirements through April 2011.
Third Quarter Highlights and Recent Developments
In June 2010, the Company entered into a license and commercialization agreement with IFF, a global leader in the food and beverage industry, covering the commercialization of RP44, Redpoint's all-natural sweetness enhancer. In October 2010, IFF received notification by the Flavor and Extract Manufacturers Association (FEMA) that RP44 had been determined to be Generally Recognized As Safe (GRAS), triggering a $0.5 million milestone payment which is due in November 2010.
Redpoint also recently reported that it had advanced its discovery program for all-natural enhancers of salty taste. The objective of the salt enhancer program is to identify natural flavor ingredients that can provide a significant reduction in the amount of sodium in food and beverage products, yet maintain the salty taste that consumers desire.
Redpoint is using its proprietary MOG assay technology for its salt enhancer discovery program. The MOG technology was developed specifically to deal with the complex sensory and experimental issues associated with the discovery of all-natural compounds, which are often derived from plant or fermentation sources containing complex mixtures of taste ingredients. Historically, natural tastants or enhancers have been discovered by trial and error using human tasters. The MOG is an enabling technology that facilitates high throughput screens of tastant libraries and natural product extracts by rodents trained to discriminate specific taste standards. MOG-trained rodents are "expert" taste testers capable of rapidly identifying taste from small samples with a high level of accuracy, providing an effective means of evaluating the taste properties of complex natural product extracts.
Redpoint originally developed its MOG technology to discover natural high-potency sweeteners and sweetener enhancers. More recently, Redpoint scientists have developed and optimized a high-throughput salt-taste detection system, in which MOG-trained rodents discriminate salt from other essential tastes (savory, sweet, sour, and bitter). The MOG approach will be used to evaluate the salt-tasting and salt-enhancing potential of natural sources such as fermentation products and edible plant extracts, with a focus on isolating active components from ingredients already used in the food industry.
Regarding its diabetes research program, in July 2010, the Company announced the issuance of a patent covering methods of using a high-throughput screen to discover certain modulators of the TRPm5 ion channel. In November 2010, the Company received notification that its diabetes program had been approved for a grant in the amount of approximately $0.25 million in connection with the Qualifying Therapeutic Discovery Project Program under section 48D of the Internal Revenue Code. The TRPm5 ion channel was originally identified as an important component of taste signaling circuits responsible for sensing sweet, savory, and bitter compounds on the tongue. Recently, an emerging body of scientific evidence has demonstrated that the TRPm5 ion channel is also found in the pancreas and gastrointestinal tract, suggesting a potential role in the regulation of metabolism and satiety.
Specifically, TRPm5 may be involved in the secretion of important hormones like GLP1 and insulin that control sugar uptake and metabolism. Consequently, modulators of TRPm5 could potentially find application as a new therapy for adult-onset diabetes and obesity. Redpoint is seeking a large pharmaceutical company as a partner for a collaborative research and development program to further develop its TRPm5 modulators for diabetes and obesity therapeutic applications.
About Redpoint Bio Corporation
Redpoint's understanding of the biology of taste and its relationship to metabolism, satiety, and diabetes impact both the development of healthier foods and potentially, new approaches for treating diabetes and obesity. Redpoint is developing taste modulators for the food and beverage industry with the aim of enhancing sweet and savory flavors in food and beverage products which can lead to reductions in added sugar and salt. The development of healthier and more tasteful food can contribute to improving the overall health of the world's population, since many modern diseases are related to excess dietary sugar and salt. Recent scientific research suggests that many of the same taste-signaling components found on the tongue are also expressed as part of a nutrient-sensing system located in the gastrointestinal tract which could lead to new opportunities for the discovery of novel diabetes or obesity therapeutics. For more information, please visit the Company's website at www.redpointbio.com.
Safe Harbor Statement
In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The Company's performance and financial results could differ materially from those reflected in these forward-looking statements due to, among other factors, the uncertain economic viability of production of RP44 on a commercial scale, the Company's inability to enter into additional collaboration agreements or raise additional capital to sustain operations, uncertainty inherent in the discovery phase of technological development, any efforts by third parties to invalidate or limit any patents, the marketplace acceptance of its products, the decisions of regulatory authorities, the results of clinical trials and general financial, economic, regulatory and political conditions affecting the food and beverage, biotechnology and pharmaceutical industries generally. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. The Company undertakes no obligation to update publicly any forward-looking statement.
Redpoint Bio
Scott Horvitz, 609-637-9700, ext. 207
Chief Financial Officer
The Trout Group (for Redpoint Bio):
Lee M. Stern, 646-378-2922
Redington, Inc.
Thomas Redington, 212-926-1733
(financial tables follow)
Redpoint Bio Corporation
(A Development-Stage Enterprise)
Selected Financial Information
Statements of Operations
(in thousands, except per share amounts)
Three Months
Ended September 30,
Nine Months
Ended September 30,
Research, grant and license revenue
$ -
$ -
$ 1,868
$ 500
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Interest income
Interest expense
Loss before income taxes
Income tax benefit
Net loss
$ (2,407)
$ (1,773)
$ (6,988)
$ (4,875)
Basic and diluted net loss per common share
$ (0.03)
$ (0.02)
$ (0.09)
$ (0.06)
Weighted average common shares outstanding
Condensed Balance Sheets
(in thousands)
December 31,
September 30,
Cash and cash equivalents
$ 5,557
$ 1,637
Other current assets
Property and equipment, net
Other assets
Total assets
$ 6,775
$ 2,456
Current liabilities
$ 1,223
$ 1,653
Long-term liabilities
Stockholders' equity
Total liabilities and stockholders' equity
$ 6,775
$ 2,456
SOURCE Redpoint Bio Corporation

subset: commoncrawl


text:
5 Tips to Avoid Holiday Shopping Hassle
Holiday shopping can really be a hassle. Not only are you dealing with all the rushing around, bargain hunting, last minute plans, crowds and traffic, but there's also safety issues, budget concerns, and how to make sure you're getting the most value for your money.
Here are 5 short videos that give strategies for shopping in stores and online that will work for you – not only during the holiday shopping season, but throughout the year – with tips on when, where, and how to shop to receive the most bang for your buck with the least amount of hassle.
Hassle-Free Holiday Shopping – Personal finance expert Carmen Wong Ulrich gives tips to stretch your holiday shopping dollars & get the most bang for your buck. Discounted gift cards, price matching, Black Friday, and online shopping tips.
Holiday Shopping Survival Tips – Between overcrowded malls and strict return policies, the shopping season can be stressful. Consumer Correspondent Susan Koeppen gives CBS's Rebecca Jarvis her smart shopping survival tips for the holidays.
Pay with Paper or Plastic for Gifts? – It is better to pay with cash, credit card, open new accounts, lay-a-way? Wall Street Journal Columnist, Wendy Bounds gives tips on best ways to pay for holiday purchases from gift cards to electronics to apparel and pitfalls to watch out for.
Scouring for Holiday Sales -CBS business and economics correspondent, Rebecca Jarvis, gives her top Web sites & mobile apps to find the best bargain-basement holiday shopping deals.
Saving on Holiday Shopping – Holiday shopping? Some creative and easy tips to, stretch your dollar, stay in control of your spending & save money while enjoying holiday gift-giving from MoneyTalksNews.com's Stacy Johnson.
Link to this article: http://is.gd/DvLx5O


text:
Joseph Parambil, MD
Primary Location
Cleveland Clinic Main Campus
- Appointment:
- 216.444.6503
- Desk:
- 216.444.7567
- Fax:
- 216.445.8160
Treatment & Services
- Diagnosing Asthma
- Treating Asthma With Bronchodilators
Specialty in Diseases & Conditions
- Bronchitis
- Cough
- Hereditary Hemorrhagic Telangiectasia
- Hypersensitivity Pneumonitis
- Langerhans Cell Histiocytosis (LCH)
- Lung Cancer
- Lung Nodules
- Lymphangioleiomyomatosis (LAM)
- Pneumonia
- Pulmonary Disease
- Pulmonary Embolism
- Pulmonary Hypertension
- Sarcoidosis
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.View All Plans
About Joseph Parambil, MD
He earned his medical degree from Semmelweis Medical University in Budapest, Hungary. He completed a surgical internship at Frankford Hospital in Philadelphia, PA. He completed an internal medicine residency at Henry Ford Hospital in Detroit, Mich., as well as a Fellowship in pulmonary and critical care medicine at Mayo Clinic in Rochester, Minn.
He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine.
Dr. Parambil is a member of several professional societies, including the American College of Physicians, the American Society of Internal Medicine, American College of Chest Physicians, American Thoracic Society and Pulmonary Hypertension Association.
He has presented a number of times on topics such as disease pathology, connective tissue disorders, and the causes and associations of pulmonary infarctions, among many others. He has also published a number or articles in peer-reviewed journals, as well as having published a number of abstracts and a book chapter on pulmonary hypertension and interstitial lung diseases. He is currently the Director of the HHT Center of Excellence.
Education & Professional Highlights
Education & Fellowships
Fellowship - Mayo Clinic
Pulmonary / Critical Care
Rochester, MN USA
Residency - Henry Ford Hospital
Internal Medicine
Detroit, MI USA
Internship - Aria Health - Frankford Hospital
Transitional Medicine
Philadelphia, PA USA
Medical School - Semmelweis Medical University
Specialty Interests
Hypersensitivity pneumonitis, langerhans cell histiocytosis (LCH), lung cancer, lymphangioleiomyomatosis (LAM), pulmonary fibrosis, pulmonary hypertension, sarcoidosis, hereditary hemorrhagic telangiectasia. Asthma, chronic obstructive pulmonary disease (COPD), emphysema, hypersensitivity pneumonitis, langerhans cell histiocytosis (LCH), lung cancer, lymphangioleiomyomatosis (LAM), pulmonary fibrosis, pulmonary hypertension, sarcoidosis
Research & Publications
See publications for Joseph Parambil, MD.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 3/7/2017, Dr. Parambil has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
296 Patient Satisfaction Reviews
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Cleveland Clinic.
|Star Ratings
|Courtesy, Respect & Concern
|Knows Medical History
|Time Spent with Patient
|Patient Rating of Doctor
31 Patient Comments
Reviewed on Jul 6, 2017
I am very impressed with concern and respect provided @ the Cleveland clinic. Dr. Parambil offers superb service. I feel comfortable asking questions.
Reviewed on May 27, 2017
Reviewed on May 9, 2017
Dr Parambil has a wonderful bedside manner. He's very kind.
Reviewed on May 8, 2017
Dr. Parambil is thorough and answers all questions.
Reviewed on May 2, 2017
Excellent physician who has always been informative about my condition and prognosis - he has kept me on track to stability and improvement with my scleroderma issues.
Reviewed on Apr 27, 2017
Brief visit summary would be helpful in remembering instructions.Doctor did not work on his computer during the visit. Great attention given to patient.
Reviewed on Apr 17, 2017
All appointments from x-ray, pulmonary function testing and with Dr. Parambil are exceptional. I have the utmost respect for Dr. Parambil. The treatment he has provided to me for the last 2 years and our appointments to the Cleveland Clinic are unmatched. Dr. Parambil is the best doctor I have been associated with for my pulmonary treatment.
Reviewed on Mar 31, 2017
excellent service
Reviewed on Mar 16, 2017
Dr Parambil is the greatest!!! professionally and socially, he has a way of making me feel safe and secure with my disease and everything will be ok
Reviewed on Feb 24, 2017
Very good
Reviewed on Feb 22, 2017
always takes the time to explain meds and next steps
Reviewed on Jan 16, 2017
Dr. Parambil is a wonderful doctor and person.
Reviewed on Jan 4, 2017
once you are able to talk with the doctor he takes the time to listen and explain each step.
Reviewed on Dec 19, 2016
When I see him I most usually have had a setback or am having issues. I saw him on Monday, could barely walk, was feeling SO bad and today, Friday, I'm running around all day doing housework, wrapping gifts, cooking, baking, and candy making for friends and family. I couldn't even begin to do that last week. His advice is always so on point.
Reviewed on Dec 8, 2016
Took into consideration I was not tolerating a particular drug very well and took steps to back off on it while monitoring my condition a little more frequently.
Reviewed on Dec 8, 2016
I've been seeing Dr. Parambil for about 9 years for pulmonary fibrosis from scleroderma. From the beginning he has answered all my questions, explained things clearly, and made sure we were "on the same Page" with tests and treatments.
Reviewed on Dec 1, 2016
I am extremely satisfied with the care provided by Dr. Parambil. His medical knowledge,plan of care,compassion, and professionalism are the best I have experienced.He does not rush and truly cares for his patients. I feel very fortunate to have him as my physician.
Reviewed on Nov 9, 2016
All was good
Reviewed on Nov 8, 2016
This is my 2nd appointment with this provider. I find him to be extremely helpful, knowledgeable, compassionate, and a pleasure to work with. He clearly cares about his patients and I feel more confident asking questions with him.
Reviewed on Nov 7, 2016
Nothing but great things to say about Dr. Parambil.
Reviewed on Nov 2, 2016
I had no medication this time. One thing I like so much about Dr. Parambil is that he covers all bases when I meet with him. I never leave there being uncertain of anything. I feel that he always knows what is important and what has to be discussed.
Reviewed on Oct 20, 2016
Dr. Parmabil, as a professor in the Lerner Medical College, is very up-to-date on my condition, the current research and insights to my disease (scleroderma), and the medications that are proving successful to keep my lung function stable. I appreciate the body of knowledge and treatment program that he has guided me through.
Reviewed on Oct 10, 2016
Wonderful care. Knowledgeable and easy to understand. He takes interest and concerned with patients. Very kind. Easy to follow his directions. Gives great care!!
Reviewed on Oct 5, 2016
Excellent experiences!!!!
Reviewed on Sep 30, 2016
Doctor Parambil goes above and beyond explaining health conditions, medications and the benefits the medication provides.
Reviewed on Sep 26, 2016
I would recommend cc to everyone
Reviewed on Sep 16, 2016
commend dr preambil
Reviewed on Sep 14, 2016
Dr Parambil and I collaborate with my advanced stage of rare lung disease in a productive manner.
Reviewed on Sep 9, 2016
Dr Parambil is the most courteous doctor ever. He will take me in early when he has time so I don't have to wait. this is the first time at twinsburg location. so I wasn't sure about it but I like it very much.
Reviewed on Sep 1, 2016
Over the years I have always been amazed at the streamlined care. I have blood work, x-rays prior to visiting Dr. Parambil and he has results by the time I see him. We are always treated with respect.
Reviewed on Aug 24, 2016
I had a very good experience!!! the CC never ceases to amaze me.
© 2017 The Cleveland Clinic Foundation. All Rights Reserved. No part of this work may be altered, reproduced, stored in a retrieval system, or transmitted, in any form, by any means, whether electronic, mechanical, by photocopying, recording, or otherwise, without the prior written permission of the Cleveland Clinic.


text:
Buying a houseboat is a great way to bring friends and family together. Designed to offer lake house living on the water complete with spacious floor plans and modern amenities for entertaining, dining and sleeping, houseboats are made for relaxing cruises, weekend getaways to boating destinations, and unlimited family boating fun. Houseboats are best suited for rivers, lakes and coastal waterways. Great for boaters of all ages, houseboats are built in a wide selection of sizes and styles and can be customized to personal tastes.
Quick Stats
- overnight cruising
- day cruising
- N/A Max
- 25 - 100 ft
- outboard engine
- inboard engine
- sterndrive engine
- not trailerable
Dealers and Manufacturers
Sign up to receive information from dealers and manufacturers on various boat types and models.Contact Dealers and Manufacturers
* Price Range varies depending on size, make and model of the boat.


text:
Austerity and fraud under different structures of technology and resource abundance
We present the implications of a simple analytical theory in which economic crisis emerges from rising real resource costs in systems with high fixed costs relative to variable costs. We show the integral role played by financial fraud in this process, and explain the effects of austerity and stimulus policies in the face of crisis under differing combinations of fixed and variable costs. Copyright The Author 2012. Published by Oxford University Press on behalf of the Cambridge Political Economy Society. All rights reserved., Oxford University Press.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Volume (Year): 36 (2012)
Issue (Month): 1 ()
Pages: 335-343
|Contact details of provider:
| Postal: Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK
Fax: 01865 267 985
Web page: http://www.cje.oupjournals.org/
|Order Information:
|Web: http://www.oup.co.uk/journals
No references listed on IDEAS
You can help add them by filling out this form.
This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.
When requesting a correction, please mention this item's handle: RePEc:oup:cambje:v:36:y:2012:i:1:p:335-343. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Oxford University Press)or (Christopher F. Baum)
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.